Please assess the completion status of the following clinical trial:

Trial Title: Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men ≥ 18 years of age and older with confirmed (histologically or cytologically) adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features~* Human leukocyte antigen (HLA)-A2.1 positive~* Asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)~* Metastatic castrate-resistant disease defined as one or more of the following criteria that occurred while the patient was on androgen deprivation therapy:~  * Prostate-specific antigen (PSA)-progression defined by Prostate Cancer Working Group 2 (PCWG2) criteria by a minimum of two rising PSA levels with an interval of ≥ 1 week between each determination~ * Progression of nodal metastases defined by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria or progression on successive magnetic resonance imaging lymphangiographies (MRLs)~ * Bone disease progression defined by two or more new lesions on bone scan as described in PCWG2 criteria~* Maintenance of castrate circumstances:~  * Ongoing primary androgen deprivation therapy (Gonadotropin-Releasing hormone agonist or antagonist) or bilateral orchiectomy~ * Serum testosterone level ≤ 1.73 nmol/L (50 ng/dL) at screening visit~* PSA value ≥ 2 ng/ml~* Absence of visceral metastases, malignant ascites or pleural effusion~* Clinical absence of brain metastases~* Inclusion within three months after the moment of manifestation of progressive disease as defined above~* Chemotherapy naive~* Life expectancy ≥ 6 months~* World Health Organization/Eastern Cooperative Oncology Group performance status 0-1 (Karnofsky index 100-70)~* White blood cells \>2.0x109/l, neutrophils \>1.5x109/L, lymphocytes \>0.8x109/L, platelets \>100x109/L, hemoglobin \>5,6 mmol/L (9.0 g/dL), serum creatinine \<150 µmol/L, aspartate aminotransferase/alanine aminotransferase \<3 x upper limit of normal (ULN), serum bilirubin \<1.5 x ULN (exception: Gilbert's syndrome is permitted)~* Expected adequacy of follow-up~* Written informed consent~Acceptable concomitant therapy:~* The use of oral or intravenous bisphosphonates~* Radiotherapy for pain relief in patients with bone metastases may be used as a treatment modality, but the need for a radiotherapeutic intervention during the study will be documented as an skeletal-related event (SRE)~* Inhaled corticosteroids and topical creams for small body areas are permitted~Exclusion Criteria:~* Hypercalcemia~* History of any second malignancy in the previous five years, with the exception of adequately treated basal cell carcinoma~* Known allergy to shell fish~* Heart failure (New York Heart Association class III/IV)~* Serious active infections~* Active hepatitis B, C or HIV infection~* Active syphilis infection~* Autoimmune diseases (exception: vitiligo is permitted)~* Organ allografts~* An uncontrolled co-morbidity, e.g. psychiatric or social conditions interfering which participation~* Previous treatment with sipuleucel-T,PROSTVAC, GVAX, chemotherapy, ipilimumab or denosumab (previous treatment with abiraterone acetate, ketoconazole or enzalutamide is permitted)~* Treatment with flutamide, bicalutamide, or nilutamide within four weeks of study enrollment~* Prior radiotherapy within four weeks prior to planned vaccination or presence of treatment-related toxicity~* Continued use of non-steroidal anti-inflammatory drugs~* Concurrent use of systemic corticosteroids \> 10 mg daily prednisone equivalent~* Requirement of opiate use for cancer-related pain (at screening)~* Any serious clinical condition that may interfere with the safe administration of DC vaccinations

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Myeloid dendritic cells (mDC) vaccinations (Type: EXPERIMENTAL): Patients will be vaccinated intranodally three times biweekly with mDC (5x 106 cells; n=7, arm A). DC will be loaded with major histocompatibility complex (MHC) class I binding peptides of tumor antigens and NY-ESO-1 and MUC1 PepTivator® which covers the complete antigen. DC will be stimulated with protamine/mRNA and loaded with keyhole limpet hemocyanin (KLH) as an immune control.
- Plasmacytoid dendritic cells (pDC) vaccinations (Type: EXPERIMENTAL): Patients will be vaccinated intranodally three times biweekly with pDC (3x 106 cells; n=7, arm B). DC will be loaded with MHC class I binding peptides of tumor antigens and NY-ESO-1 and MUC1 PepTivator® which covers the complete antigen. DC will be stimulated with protamine/mRNA.
- mDC and pDC vaccinations (Type: EXPERIMENTAL): Patients will be vaccinated intranodally three times biweekly with the combination of mDC and pDC (5x 106 mDC/ 3x 106 pDC; n=7, arm C). DC will be loaded with MHC class I binding peptides of tumor antigens and NY-ESO-1 and MUC1 PepTivator® which covers the complete antigen. DC will be stimulated with protamine/mRNA and loaded with KLH (mDC only) as an immune control.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete